| Literature DB >> 33754510 |
Jay Chol Choi1,2, Joong Goo Kim1, Chul Hoo Kang1, Hee Joon Bae3, Jihoon Kang3, Soo Joo Lee4, Jong Moo Park5, Tai Hwan Park6, Yong Jin Cho7, Kyung Bok Lee8, Jun Lee9, Dong Eog Kim10, Jae Kwan Cha11, Joon Tae Kim12, Byung Chul Lee13, Ji Sung Lee14, Anthony S Kim15.
Abstract
BACKGROUND: We investigated the association between geographic proximity to hospitals and the administration rate of reperfusion therapy for acute ischemic stroke.Entities:
Keywords: Endovascular Treatment; Ischemic Stroke; Reperfusion; Thrombolysis; Utilization
Year: 2021 PMID: 33754510 PMCID: PMC7985286 DOI: 10.3346/jkms.2021.36.e77
Source DB: PubMed Journal: J Korean Med Sci ISSN: 1011-8934 Impact factor: 2.153
Characteristics of patients by estimated ground transport time
| Characteristics | 0–30 min (n = 7,837) | 31–60 min (n = 2,958) | 61–90 min (n = 949) | 91–120 min (n = 335) | > 120 min (n = 93) | |||
|---|---|---|---|---|---|---|---|---|
| Demographic characteristics | ||||||||
| Age, yr | 67 ± 13 | 67 ± 12 | 69 ± 12 | 69 ± 11 | 71 ± 11 | < 0.001 | ||
| Male sex | 4,657 (59.4) | 1,815 (61.4) | 556 (58.6) | 193 (57.6) | 48 (51.6) | 0.600 | ||
| Medical history | ||||||||
| Hypertension | 5,257 (67.1) | 1,912 (64.6) | 605 (63.8) | 214 (63.9) | 55 (59.1) | 0.001 | ||
| Diabetes mellitus | 2,367 (30.2) | 826 (27.9) | 259 (27.3) | 90 (26.9) | 16 (17.2) | < 0.001 | ||
| Atrial fibrillation | 2,159 (27.5) | 820 (27.7) | 297 (31.3) | 121 (36.1) | 39 (41.9) | < 0.001 | ||
| Hyperlipidemia | 2,417 (30.8) | 921 (31.1) | 251 (26.4) | 65 (19.4) | 19 (20.4) | < 0.001 | ||
| Current smoking | 1,991 (25.4) | 804 (27.2) | 225 (23.7) | 80 (23.9) | 10 (10.8) | 0.144 | ||
| History of stroke | 1,721 (22.0) | 612 (20.7) | 196 (20.7) | 70 (20.9) | 22 (23.7) | 0.272 | ||
| History of CAD | 810 (10.3) | 299 (10.1) | 82 (8.6) | 20 (6.0) | 9 (9.7) | 0.015 | ||
| Medication history | ||||||||
| Antiplatelet agents | 2,357 (30.1) | 865 (29.2) | 243 (25.6) | 79 (23.6) | 19 (20.4) | < 0.001 | ||
| Oral anticoagulants | 476 (6.1) | 170 (5.7) | 55 (5.8) | 16 (4.8) | 7 (7.5) | 0.485 | ||
| Statin | 1,271 (16.2) | 440 (14.9) | 124 (13.1) | 34 (10.1) | 10 (10.8) | < 0.001 | ||
| Clinical characteristics | ||||||||
| Onset-to-arrival time (IQR), min | 176 (65–389) | 216 (107–405) | 251 (154–402) | 270 (182–416) | 298 (221–479) | 0.001 | ||
| Initial NIHSS score | 4 (2–11) | 5 (2–13) | 6 (2–14) | 8 (3–14) | 9 (4–15) | < 0.001 | ||
| TOAST classification | 0.038 | |||||||
| LAA | 2,503 (31.9) | 946 (32.0) | 302 (31.8) | 104 (31.0) | 21 (22.6) | |||
| CE | 2,291 (29.2) | 882 (29.8) | 314 (33.1) | 125 (37.3) | 41 (44.1) | |||
| SVO | 1,183 (15.1) | 438 (14.8) | 105 (11.1) | 26 (7.8) | 7 (7.5) | |||
| UDE or ODE | 1,860 (23.7) | 692 (23.4) | 228 (24.0) | 80 (23.9) | 24 (25.8) | |||
| Laboratory values | ||||||||
| Systolic blood pressure, mmHg | 148 ± 28 | 147 ± 27 | 144 ± 25 | 140 ± 24 | 140 ± 24 | < 0.001 | ||
| Diastolic blood pressure, mmHg | 86 ± 17 | 86 ± 16 | 86 ± 15 | 84 ± 14 | 86 ± 14 | 0.682 | ||
| Fasting glucose, mg/dL | 124 ± 51 | 123 ± 48 | 123 ± 46 | 129 ± 48 | 133 ± 59 | 0.012 | ||
| LDL cholesterol, mg/dL | 108 ± 36 | 108 ± 36 | 110 ± 37 | 110 ± 37 | 112 ± 32 | 0.018 | ||
| Hemoglobin, g/dL | 14 ± 2 | 14 ± 2 | 13 ± 2 | 13 ± 2 | 13 ± 2 | < 0.001 | ||
| Platelet counts, 103/μL | 231 ± 75 | 225 ± 71 | 224 ± 73 | 225 ± 78 | 204 ± 56 | < 0.001 | ||
| BUN, mg/dl | 17 ± 9 | 17 ± 9 | 17 ± 9 | 17 ± 8 | 20 ± 14 | 0.812 | ||
| Residential and travel information | ||||||||
| Residence | < 0.001 | |||||||
| Metropolitan | 4,933 (62.9) | 853 (28.8) | 75 (7.9) | 10 (3.0) | - | |||
| Urban | 2,839 (36.2) | 1,565 (52.9) | 457 (48.2) | 154 (46.0) | 14 (15.1) | |||
| Rural | 65 (0.8) | 540 (18.3) | 417 (43.9) | 171 (51.0) | 79 (84.9) | |||
| Transport time (IQR), min | 17 (11–23) | 41 (35–50) | 71 (66–78) | 101 (95–107) | 136 (124–146) | < 0.001 | ||
| Travel distance (IQR), km | 6 (3–9) | 27 (18–39) | 71 (57–85) | 115 (98–123) | 145 (137–156) | < 0.001 | ||
| Thrombolytic therapy | 0.008 | |||||||
| None | 5,645 (72.0) | 2,140 (72.3) | 645 (68.0) | 219 (65.4) | 69 (74.2) | |||
| IVT alone | 1,432 (18.3) | 507 (17.1) | 186 (19.6) | 74 (22.1) | 17 (18.3) | |||
| EVT or combined therapy | 760 (9.7) | 311 (10.5) | 118 (12.4) | 42 (12.5) | 7 (7.5) | |||
Data are presented as number (%) or mean ± standard deviation.
IQR = interquartile range, NIHSS = National Institutes of Health Stroke Scale, LAA = large artery atherosclerosis, CE = cardioembolism, SVO = small-vessel occlusion, UDE = undetermined etiology, ODE = other determined etiology, LDL = low-density lipoprotein, BUN = blood urea nitrogen, IVT = intravenous thrombolysis, EVT = endovascular therapy.
Fig. 1Patient distribution by reperfusion therapy.
CRCS-K = The Clinical Research Collaboration for Stroke in Korea, IVT = intravenous thrombolysis, EVT = endovascular therapy.
Fig. 2Estimated proportion of the patients received reperfusion therapy by ground transport time.
(A) IVT, unadjusted analysis (P = 0.003); (B) IVT, adjusted analysis (P = 0.006); adjusted for age, hypertension, diabetes, atrial fibrillation, stroke history, coronary artery disease, use of an antiplatelet agent, oral anticoagulants or statins before the index stroke, diastolic blood pressure, fasting blood glucose, low-density lipoprotein cholesterol, platelet count, onset-to-arrival time, initial NIHSS score, and TOAST classification. (C) EVT, unadjusted analysis (P = 0.090); (D) EVT, adjusted analysis (P = 0.100); adjusted for age, sex, hypertension, diabetes, atrial fibrillation, hyperlipidemia, smoking, coronary artery disease, use of an antiplatelet agent or oral anticoagulants before the index stroke, systolic blood pressure, hemoglobin, platelet count, blood urea nitrogen, onset-to-arrival time, initial NIHSS score, and TOAST classification.
IVT = intravenous thrombolysis, EVT = endovascular therapy, NIHSS = National Institutes of Health Stroke Scale, TOAST = Trial of Org 10172 in Acute Stroke Treatment.
Fig. 3Left map shows the residential areas (black) of Korea (A). The service area map on the right shows service areas accessible from the 67 stroke centers accredited by the Korean Stroke Society within each ground transport time threshold (B).
Proportion of stroke patients from CRCS-K hospitals and the estimated proportion of Korean population from 67 accredited stroke centers by each ground transport time threshold
| Hospital | Target population or region | ≤ 30 min | ≤ 60 min | ≤ 90 min | ≤ 120 min |
|---|---|---|---|---|---|
| From 12 CRCS-K centers | CRCS-K population | 64.4% | 88.7% | 96.5% | 99.2% |
| From 67 accredited stroke centers | Total land area of Korea | 11.0% | 54.8% | 82.6% | 92.9% |
| From 67 accredited stroke centers | Residential area of Korea | 73.0% | 93.2% | 98.4% | 99.6% |
CRCS-K = The Clinical Research Collaboration for Stroke in Korea.